Braveheart Bio priced a $382 million IPO, with underwriters exercising an option to purchase more shares and pushing the company’s total proceeds to nearly $440 million. The clinical-stage firm’s lead program targets cardiomyopathy and is framed as potentially competitive with Bristol Myers Squibb’s blockbuster therapy in the same disease area. The offering underscores continued investor appetite for late-stage clinical narratives in cardiovascular medicine, especially where a new mechanism or differentiated patient profile could widen the addressable market. Braveheart’s capital raise also provides runway for pivotal-stage execution and follow-on studies. In the same week, IPO activity in biotech accelerated, with Braveheart’s transaction serving as a benchmark for deal size and clinical momentum. The company’s next steps will likely center on advancing its lead asset toward the pivotal readout while protecting timelines for additional pipeline candidates.